CTI BioPharma Corporation (CTIC) オプション

Started this too!
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=pacritinib&draw=2&rank=1

Huh!

https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2
Who knows if we will know some data before the closing of the deal?

now we can spend!
https://clinicaltrials.gov/ct2/show/NCT05552183?cond=pacritinib&draw=2&rank=2
https://clinicaltrials.gov/ct2/history/NCT05552183
https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
https://clinicaltrials.gov/ct2/history/NCT05657613

How sad all the difficulties encountered for JB's cunning!
After all, those who pay the most are the sick since time is the most precious thing we have!

Is it possible that there is no one willing to up the ante a bit?

congrat$

Congrats longs!

Sobi's got a deal!
If it goes wrong they take 59 million!
It could happen

In the event of a termination of the Merger Agreement under certain specified circumstances, including (i) termination by CTI to enter into an agreement providing for a Superior Offer (provided that CTI did not materially breach its non-solicitation obligations in any manner that results in such Superior Offer), (ii) termination by Sobi following a Company Adverse Recommendation Change, (iii) termination by Sobi due to the CTI board of directors’ failure to include its recommendation in the Schedule 14D-9, (iv) termination by Sobi because CTI has materially breached its obligations in respect of the non-solicitation provisions in the Merger Agreement, or (v) termination by either CTI or Sobi if the closing of the transactions contemplated by the Merger Agreement has not occurred by the Outside Date or termination by Sobi prior to the Offer Acceptance Time if CTI breaches its representations, warranties or covenants in the Merger Agreement in a way that would cause certain conditions of the Offer not to be satisfied (subject to CTI’s right to cure the breach as set forth in the Merger Agreement prior to such time of termination), and (A) a bona fide “Acquisition Proposal” (as defined in the Merger Agreement) has been publicly disclosed after the date of the Merger Agreement and (B) within twelve months following such termination, CTI signs a definitive agreement for an Acquisition Proposal or consummates an Acquisition Proposal, in each case of the foregoing clauses (i)-(v), CTI is required to pay Sobi a termination fee equal to $59,000,000.
This summary is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 hereto and incorporated by reference herein.

BOOM!
MANY THANKS TO ADAM!
The price seems low to me, let's hope someone raises it!
Congratulations to all who are enjoying!

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00523

Hey HD did you buy any CTIC yet…..come Tuesday morning I’ll have 38k

Ctic and gern might be merging….

https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2
really started

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8

Why did they bring it up early in the morning?
seems unusual to me!

FDA approval of VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
$54 million in net sales in the first nine months following VONJO launch.
Over 1,000 patients commercially treated with VONJO in 2022.
Inclusion in the National Comprehensive Cancer Network® (NCCN®)
Oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition highlighted pacritinib as a potent activin A receptor type 1 (ACVR1) inhibitor with significant anemia benefit in patients with myelofibrosis. A receptor type 1 (ACVR1) inhibitor and anemia benefit. We look forward to continuing activities focused on market expansion in 2023, which are intended to drive quarter-over-quarter net sales increases
On February 7, 2023, VONJO was granted seven years of orphan-drug exclusive approval by the FDA for treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x109/L. The seven-year exclusive approval began on February 28, 2022.

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8
no sneak peeks on last quarter's sales

Upcoming Events
SVB Securities Global Biopharma Conference
Feb 15, 2023 at 3:40 PM EST
Guggenheim Partners 5th Annual Oncology Conference
Feb 8, 2023 at 10:45 AM EST

Well, won't he say anything about the year that just ended?

https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
Actual Study Start Date : January 3, 2023

Net VONJO sales of $32.9M since launch in March 2022*

tomorrow it's Adam Craig's turn with capsule therapy

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8

https://clinicaltrials.gov/ct2/show/NCT05657613?cond=pacritinib&draw=2&rank=3
NEW

started
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=pacritinib&draw=2

Stephen Oh, MD, PhD, Associate Professor of Medicine, Hematology Division at Washington University School of Medicine in St. Louis. "As anemia poses a substantial burden for patients with myelofibrosis, the potential role of pacritinib in addressing anemia is highly encouraging."

"As our understanding of the mechanism of action of pacritinib expands, the full potential of pacritinib as a therapy for cytopenic myelofibrosis is emerging," said Adam Craig, MD, PhD, President and Chief Executive Officer of CTI BioPharma. "We continue in our commitment to meaningfully change the treatment paradigm for cytopenic myelofibrosis."

https://wsw.com/webcast/stifel74/register.aspx?conf=stifel74&page=ctic&url=https://wsw.com/webcast/stifel74/ctic/2075894
Today

https://wsw.com/webcast/jeff255/ctic/1835973
i like Adam Craig

who will buy today or tomorrow?
https://fintel.io/sst/us/ctic

180 milion share outstanding
17 milion short!
I see it for $ 10 because PAC is the best
and the FDA are taking notice
JB was right
JB was right
JB was right
JB was right
JB was right
JB was right
JB was right

Graig but why don't you propose to Pfizer to try PAC?
https://www.fiercepharma.com/pharma/europe-will-look-at-all-jak-inhibitors-following-safety-concerns-raised-trial-pfizer-s

owls are in no hurry!
https://www.youtube.com/shorts/yPm0Yqx2mcE

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8

In the third quarter, CTI continued to make strong progress with the U.S. commercial laun ch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.

IMO, careful cost management will lead to higher margins

made the due proportions...
INCY
Jakafi’s (a first-in-class JAK1/JAK2 inhibitor approved for polycythemiavera, myelofibrosis and refractory acute graft-versus-host disease) revenues came in at $619.5 million.
Jakafi® (ruxolitinib) net product revenues of $598 million in Q2’22 (+13% Y/Y) driven by volume growth; raising the bottom end of full year guidance to new range of $2.36 to $2.40 billion

https://www.targetedonc.com/view/reactions-to-the-latest-data-on-jak-inhibition-for-myelofibrosis
Who knows what the plans are? nothing in europe?
Could PAC be used in the remautological space given the problem of other inhibitors?
liquid shit but maybe it's better than thrombotic events

https://fintel.io/so/us/ctic
Institutional Shares (Long) 94,105,342 - 82.27%
Insider Ownership 13.84%

but someone….brrrrrr
https://fintel.io/sst/us/ctic

https://fintel.io/so/us/ctic
Institutional Shares (Long) 94,105,342 - 82.27%
Insider Ownership 13.84%

but someone….brrrrrr
https://fintel.io/sst/us/ctic

Jim Fong, the Company’s Chief Commercial Officer, has been promoted to Executive Vice President and Chief Commercial Officer, and will begin reporting directly to the Company’s Chief Executive Officer.
sounds good to me
Who knows why they promoted him?

NEW
https://clinicaltrials.gov/ct2/show/NCT05552183?cond=pacritinib&draw=2&rank=2

Pacritinib is a JAK2/IRAK1/CSF1R/FLT3 inhibitor, with an established safety and efficacy profile in the treatment of myeloproliferative neoplasms (myelofibrosis) and of acute GVHD.
Pacritinib s immunomodulatory effects suggest therapeutic benefit for cGVHD, without abrogating the graft-versus-leukemia effect after HSCT.
Start - 20

NEW
https://clinicaltrials.gov/ct2/show/NCT05531786?cond=PACRITINIB&draw=3&rank=21

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8

https://clinicaltrials.gov/ct2/show/NCT04858256?cond=Pacritinib&draw=2&rank=1
it seems to be starting soon

https://clinicaltrials.gov/ct2/show/NCT02891603
what will they do?

pacritinib sales will be strong!
the drug is used after ruxolitinib...

Why is everything stopped? At least it seems
https://clinicaltrials.gov/ct2/show/NCT04858256?cond=pacritinib&draw=2&rank=1

https://investors.ctibiopharma.com/static-files/83278a88-ff8f-457a-bccf-1900fe5042d8

Nice, $10 price target https://www.marketscreener.com/quote/stock/CTI-BIOPHARMA-CORP-32713095/news/Cowen-Starts-CTI-BioPharma-at-Outperform-With-10-Price-Target-40919991/

here willing to recover! so much has been given it is time to receive

Huh
7
Yeah!

So the second quarter is closed! We will have a more realistic sales projection!
I imagine Robocop busy presenting them, always interesting how he frames things!
For the rest it seems to me that everything has stopped!
So something comes to me

something makes me think of a BO